reference/13406574

Predicate	Object
contentType	Journal Article
endingPage	14
issn	1179-5549
pageRange	CMO.S8536-14
publicationName	Clinical Medicine Insights: Oncology
startingPage	CMO.S8536
bibliographicCitation	Rodd AL, Ververis K, Karagiannis TC. Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma. Clin Med Insights Oncol. 2012;6():305–14. PMID: 23032692; PMCID: PMC3459669.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7adf0b663c42030bfe75536d704ab4f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f40d903f8a715c760154a3b979f1d705 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2325c3c85f8be72e648182d1f8ec915
date	201201
identifier	https://pubmed.ncbi.nlm.nih.gov/23032692 https://pubmed.ncbi.nlm.nih.gov/PMC3459669 https://doi.org/10.4137/cmo.s8536
isPartOf	https://portal.issn.org/resource/ISSN/1179-5549 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37328
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148121 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID126941 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9861 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_6.3.2.17 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID175427094 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243124404 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128866026

Total number of triples: 28.